NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported
biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.
See the complete Press Release.
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
Applied Therapeutics, Inc. has announced that their drug candidate, AT-007 (Govorestat), has received orphan medicinal product designation
Clinical Trial Update for SORD Deficiency – Applied Therapeutics – Dr. Shoshana Shendelman
HNF Partner Applied Therapeutics is Currently Enrolling SORD Deficiency Patients for the INSPIRE Phase III Clinical Trial
Join us for this webinar as we learn more about Sorbitol Dehydrogenase (SORD) Deficiency
Press Release
A new type of Charcot-Marie-Tooth (CMT) has recently been identified caused by mutations in the SORD gene.
a mutation in the SORD gene that may may affect 60,000 patients worldwide
0 Comments